Dynamic MapReport

World News   USA   California   Bay Area   Foster City   Business   Bio Tech (14)
Foster City, Bio Tech Timeline Tuesday, May 1 Bookmark and Share     Author
Search Bay Area News Atlas:

Gilead Sciences CEO joins billionaires' ranks  John Martin is $1.2 billion, based on his stake in the company, which recently released a potential blockbuster drug to treat Hepatitis C Gilead profit beats estimates  Gilead Sciences Inc., the world's largest maker of HIV medicines, has reported net income in the fourth quarter rose 3.8 percent to $791.4 m... Gilead to buy Pharmasset for $11 billion
World News (13) World Bio Tech (28) USA (336) California (187) Bay Area (12) Bay Area Bio Tech (139) Foster City (65) Business (30) Bio Tech (14)
Aids Drug (2)
2017 (1) 2016 (1) 2015 (2) 2014 (2) 2011 (1) 2009 (3) 2008 (1) 2003 (1) 2002 (2)
Bio Tech on Wikipedia Bio Tech on Web

Gilead (13)   Peninsula Merger and Acquisition (78)
Gilead Sciences beats estimates for 4th-quarter earnings   34 percent increase in profit, trouncing expectations, as sales of its blockbuster hepatitis C drugs soared in Japan and offset lower sales in the U.S Gilead Sciences beats Street 3Q forecasts  Propelled by sales of hepatitis C pills, Gilead posted an impressive 68% increase in third-quarter profit and hiked its revenue forecast yet again Gilead profit beats Wall Street forecasts
Gilead beats Street 4Q forecasts


year 2017 Top ^

Feb.7
  Gilead Sciences Inc. (GILD) on Tuesday reported fourth-quarter earnings of $3.11 billion. It had profit of $2.34 per share


year 2016 Top ^

Feb.2


year 2015 Top ^

Oct.27
Jul.28
  Blockbuster hepatitis C medicine Harvoni lifted Gilead Sciences’ second-quarter profit by 23% as total revenue for the biotech drugmaker jumped 26%



year 2014 Top ^

Mar.3
Feb.5


year 2011 Top ^

Nov.21
  Gilead Sciences Inc. has agreed to pay about $11 billion for drug developer Pharmasset Inc. in a huge bet on experimental hepatitis C treatments


year 2009 Top ^

Apr.28 Flu's bad news but shot in arm for Gilead
  Gilead Sciences climbed nearly 4 percent to close at $47.53; they're collecting on Tamiflu, the influenza drug the biotech company invented Apr.22 Lawsuit Vs. Gilead To Proceed  The U.S. Supreme Court has refused to halt a securities-fraud suit by investors who claim the biotech company inflated its stock price in 2003 Mar.12 Gilead To Buy CV Therapeutics For $1.4 B
  Biotechnology company Gilead Sciences, known for its HIV drugs, said it will pay $20 per share in cash for Palo Alto-based CV Therapeutics


year 2008 Top ^

Jun.12 Invitrogen to buy Applied Biosystems
  Invitrogen agreed to pay $6.4 billion in cash and stock for scientific instruments maker Applera's Applied Biosystems Group


year 2003 Top ^

Apr.4 Company ships AIDS drug to Africa
  Gilead Sciences has begun shipping its new drug at cost to poor countries in Africa and other regions

year 2002 Top ^

Dec.17 Gilead to slash AIDS drug price in Africa  Gilead Sciences would dramatically slash the price it charges for Viread in all of Africa and 15 other least-developed countries Dec.4 Gilead buys AIDS-fighting competitor  Gilead Sciences would acquire Triangle Pharmaceuticals for $464 million in cash




Add a favorite (file a bookmark) to Foster City, Bio Tech Timeline


Please send feedback to: support@mapreport.com

Advertise on Foster City, Bio Tech Page

XML